Prime Medicine (PRME) Income towards Parent Company (2021 - 2026)
Prime Medicine (PRME) posted Income towards Parent Company of -$228.7 million for Q1 2026, down 381.22% on a QoQ basis from -$47.5 million in Q4 2025, and down 340.77% year-over-year from $95.0 million in Q1 2025.
Prime Medicine (PRME) Income towards Parent Company (2021 - 2026) Analysis & Trends
Prime Medicine's Income towards Parent Company history runs 6 years deep, the most recent figure standing at -$228.7 million for Q1 2026.
- Quarterly Income towards Parent Company fell 340.77% year-over-year to -$228.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$453.2 million (down 124.36% YoY) and the FY2025 annual result came in at -$204.2 million, down 4.25% from the prior year.
- Income towards Parent Company was -$228.7 million for Q1 2026 at Prime Medicine, down from -$47.5 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$23.8 million in Q1 2022 and bottomed at -$228.7 million in Q1 2026.
- A 5-year average of -$60.1 million and a median of -$47.5 million in 2025 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2022 — Income towards Parent Company jumped 37.56% — and 2026, when it slumped 340.77%.
- Prime Medicine's Income towards Parent Company stood at -$39.3 million in 2022, then plunged by 67.1% to -$65.6 million in 2023, then surged by 35.6% to -$42.3 million in 2024, then fell by 12.42% to -$47.5 million in 2025, then plunged by 381.22% to -$228.7 million in 2026.
- Business Quant data shows PRME's Income towards Parent Company at -$228.7 million in Q1 2026, -$47.5 million in Q4 2025, and -$124.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Prime Medicine | 524.20 Mn | 524.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -228.71 Mn |
| Dec 31, 2025 | -47.53 Mn |
| Sep 30, 2025 | -124.40 Mn |
| Jun 30, 2025 | -52.59 Mn |
| Mar 31, 2025 | -51.89 Mn |
| Dec 31, 2024 | -42.28 Mn |
| Sep 30, 2024 | -52.52 Mn |
| Jun 30, 2024 | -55.33 Mn |
| Mar 31, 2024 | -45.76 Mn |
| Dec 31, 2023 | -65.64 Mn |
| Sep 30, 2023 | -50.71 Mn |
| Jun 30, 2023 | -42.39 Mn |
| Mar 31, 2023 | -39.40 Mn |
| Dec 31, 2022 | -39.28 Mn |
| Sep 30, 2022 | -29.35 Mn |
| Jun 30, 2022 | -29.35 Mn |
| Mar 31, 2022 | -23.84 Mn |
| Dec 31, 2021 | -62.91 Mn |
| Sep 30, 2021 | -16.41 Mn |